Interleukin-12 to interleukin 'infinity': the rationale for future therapeutic cytokine targeting.
Anderson
E J R
EJ
Division of Immunology, Infection and Inflammation, Centre for Rheumatic Diseases, University of Glasgow, Glasgow, Scotland, UK.
McGrath
M A
MA
Thalhamer
T
T
McInnes
I B
IB
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy; D003424:Crohn Disease / Q000276:immunology / Q000628:therapy; D006801:Humans; D007154:Immune System Diseases / Q000276:immunology / Q000628:therapy*; D018664:Interleukin-12 / Q000037:antagonists & inhibitors* / Q000276:immunology*; D019409:Interleukin-15 / Q000276:immunology; D020381:Interleukin-17 / Q000276:immunology; D020382:Interleukin-18 / Q000276:immunology; D007378:Interleukins / Q000037:antagonists & inhibitors* / Q000276:immunology*; D051379:Mice; D011565:Psoriasis / Q000276:immunology / Q000628:therapy
D019409:Interleukin-15; D020381:Interleukin-17; D020382:Interleukin-18; D007378:Interleukins; D018664:Interleukin-12